What question did this study set out to answer?

This review aims to evaluate the effectiveness of mirvetuximab soravtansine in treating chemotherapy-resistant ovarian cancer.

Mirvetuximab Soravtansine in the Treatment of Chemotherapy-Resistant Ovarian Cancer: A Systematic Review

View Full Paper

Ask AI

Bookmark

This review aims to evaluate the effectiveness of mirvetuximab soravtansine in treating chemotherapy-resistant ovarian cancer.
Conducted a systematic review of five publications across three clinical trials (one phase II, two phase III)
Analyzed outcomes from 925 patients with platinum-resistant ovarian cancer
Reviewed data from PubMed, ClinicalKey, and SpringerLink databases from 2019 to 2026.
The phase III MIRASOL trial showed improved median overall survival of 16.46 months with MIRV compared to 12.75 months with standard chemotherapy (HR 0.67)
Progression-free survival was longer for MIRV (5.62 months) compared to chemotherapy (3.98 months) (HR 0.65)
Objective response rate was 42.3% for MIRV against 15.9% for standard treatment.

No takes yet. Share an insight, caveat, or question.

Systematic review evaluates mirvetuximab soravtansine's effectiveness in platinum-resistant ovarian cancer, suggesting promising outcomes.

Picheta et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Systematic review evaluates mirvetuximab soravtansine's effectiveness in platinum-resistant ovarian cancer, suggesting promising outcomes.